Breaking Research News from sources other than Breastcancer.org
Comments
-
Dear Moth, there's another possibility you did not mention: ErSO might be good but is extremely cheap to sell, i.e. everyone knows it is easy to make, market and you cannot sell it wit 2000% margin, meaning that you have to invest quickly into clinical trials now and pay-off comes slowly and begins to pay off in 10 years = not very interesting for a big company (who knows what will happen in 10 years?:)... this also has already happened. Saulius
0 -
Just saw an article that said that Systems Oncoligy will be going ahead with Erso and that it may go into clinical trials for Ovarian cancer too.
0 -
Elanas401 - Wow! Fantastic news, thanks for posting. This is something to ponder; the "failed" trial with Bayer could very well be simply not a large enough profit margin as mentioned above by Saulius. Maybe Systems Oncology is more humanitarian.
Great news, thanks!
0 -
TriNeta Becomes an FDA Breakthrough Device for Early-Stage Breast Cancer Detection
The FDA has granted breakthrough device designation to TriNeta, a blood test designed to detect early-stage breast cancer, according to a press release by the developer Datar Cancer Genetic, Inc.1
The test works by detecting circulating tumor cells that are specific to breast cancer. In recent studies, TriNeta detected cancer as early as stage 0 and stage 1 with a high level of accuracy. To detect cancer, only 5 ml of blood is needed. Patients that can be tested with the device are asymptomatic women who are older than 40 years of age with a prescription from their physician.
0 -
wow, that's great news
0 -
Wow that is amazing. Wonder if there is application after diagnosis/treatment with stage 1 to determine if further years of hormonal therapy needed?
0 -
elenas401 - that is great news for ErSO. I wonder if Bayer did that press release in July just to create a buzz to increase the value of their stock. They probably thought investors would jump on it, but didn't think they would be bombarded by a large gang of menopausal breast cancer patients! I hope Systems Oncolgy succeeds without them. It would be wonderful if this drug becomes a game changer for us. Even if not a cure, perhaps better quality of life and long term remission could be achieved.
Were you able to try the Alpha Dart treatment you mentioned?
0 -
Study compares spiral breast CT, digital mammography
Researchers found that patients who underwent spiral breast CT experienced a significant reduction in discomfort and pain, especially among premenopausal women, compared with digital mammography. The findings, published in the European Journal of Radiology, also showed that using SBCT led to a "favorable" interrater agreement among radiologists and was able to consistently detect microcalcifications at a radiation dose that is comparable to digital mammography.
Full Story: Health Imaginghttps://www.healthimaging.com/topics/diagnostic-screening/patients-prefer-spiral-breast-ct-over-dm
{No charge for access to reporting.}
0 -
Age Distributions of Breast Cancer Diagnosis and Mortality by Race and Ethnicity
- The authors used data from the SEER database to identify trends in breast cancer diagnosis and mortality by race and ethnicity. Minority women were 72% more likely to be diagnosed with invasive breast cancer and 58% more likely to be diagnosed with advanced breast cancer at young ages compared with white women. Minority women were also 127% more likely to die of breast cancer at a young age.
- Minority women are disproportionately impacted by advanced breast cancer at a young age, and this should be considered when developing screening guidelines for breast cancer.
DOI: 10.1002/cncr.33846{Free access to reporting/summary and to journal article.}0 -
elenas401, can you send the link to that article? cant find anything
0 -
Anyone interested in enrolling in the op-1250 trail, don’t hesitate! Its amazing what it can do according to the clinical coordinator who shared this info with me
Link: https://drive.google.com/file/d/1FklxhTXj4N3odFI2lJscdQIUMmQ5u_ZS/view?usp=drivesdk0 -
Thanks, DeeBama, for the information on the OP-1250 trial. Sounds very encouraging.
0 -
Early research in mice...
New therapeutic approach prevents growth of metastatic tumors by putting cancer cells to sleep
...In a previous study, Maria Soledad Sosa from the Icahn School of Medicine at Mount Sinai and Julio A. Aguirre-Ghiso, now at Albert Einstein College of Medicine, discovered that the ability of cancer cells to remain dormant is controlled by a protein called NR2F1. This receptor protein can enter the cell nucleus and turn numerous genes on or off to activate a program that prevents the cancer cells from proliferating.
...In the new JEM study, Sosa and Aguirre-Ghiso's teams used a computer-based screening approach to identify a drug, named C26, that activates NR2F1. The researchers found that treating patient-derived HNSCC cells with C26 boosted the levels of NR2F1 and arrested cell proliferation.
..."Drugs that activate NR2F1 might be particularly useful in breast cancer," says Sosa. "NR2F1 is highly enriched in ER-positive tumors when compared to ER-negative tumors, and activating NR2F1 might be able to suppress reawakening of dormant cancer cells kept in that state by anti-estrogen therapies." However, because C26 treatment elevates the levels of NR2F1, the approach may also be useful for other cancers with inherently low levels of the receptor protein.
0 -
I hope so, Deee, and now I don't remember either...but it was helpful! That expains my not being able to go back and review what you said before I sent my reply!!
0 -
And the very best of luck with the trial! Keep us all posted!
0 -
AlabamaDee's account continues to be compromised. The poster above, AlabamaDeee, which started out as BamaD is NOT the real AlabamaDee. We are in contact with the real AlabamaDee and she has NOT re-registered. Please do not respond to anyone claiming to be AlabamaDee until we notify you.
Please be cautious about sharing your email addresses, or any personal information over PM.
We are working on this issue. Please contact us via PM, or to community@breastcancer.org if you have any concerns.
Warmly,
The Mods
0 -
New cancer therapy from Yibin Kang's [Princeton] lab holds potential to switch off major cancer types without side effects
Cancer biologist Yibin Kang has spent more than 15 years investigating a little-known but deadly gene called MTDH, or metadherin, which enables cancer in two important ways — and which he can now disable, in mice and in human tissue, with a targeted experimental treatment that will be ready for human trials in a few years. His work appears in two papers in today's issue of Nature Cancer...
"You can't find a drug target better than this: MTDH is important for most major human cancers, not important for normal cells, and it can be eliminated with no obvious side effects," said Kang, Princeton's Warner-Lambert/Parke-Davis Professor of Molecular Biology and one of the principal investigators of the Princeton Branch of the Ludwig Institute for Cancer Research.
"In the two papers we are publishing back-to-back today, we identify a compound, show it is effective against cancer, and show that it is very, very effective when combined with chemotherapy and immunotherapy," said Kang...
0 -
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer:
Among premenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, those who received chemoendocrine therapy had longer invasive disease–free survival and distant relapse–free survival than those who received endocrine-only therapy, whereas postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy.
0 -
Definitive Local Therapy in Select Patients With HER2+ de Novo Metastatic Breast Cancer Treated With Dual Anti-HER2 Blockade
- The authors of this retrospective study evaluated the role of local therapy in addition to systemic chemotherapy plus dual anti-HER2 agents in selected HER2-positive de novo metastatic breast cancer. There was a superior 3-year overall survival for patients who received both surgery and radiation compared with those who received surgery alone, radiation alone, or no local therapy.
- Further prospective studies are warranted to confirm the findings for select patients with HER2-positive de novo metastatic breast cancer.
Breast Cancer Res Treat 2021 Nov 17;[EPub Ahead of Print], L Rosier, Y Wang, JH Lee, K Daily{Free access to full article.}0 -
SNO 2021: Neratinib Is Promising for Leptomeningeal Metastases of Heavily Pretreated HER2+ Breast Cancer
Dr. Pellerino concluded that neratinib may be a safe and effective treatment for leptomeningeal metastases of heavily pretreated HER2-positive breast cancer. She remarked, "The study is ongoing with the aim of increasing the sample size to validate preliminary results."
Patients underwent a median of three adjuvant treatments before the onset of leptomeningeal metastases. Three patients developed leptomeningeal metastases alone. The other six harbored leptomeningeal metastases associated with multiple bone metastases. Six-month overall survival was 66.7%. One-year overall survival was 22.3%. Median overall survival was 8 (95% confidence interval 3 - 13) months. Median progression-free survival was 3.5 (95% confidence interval 2 - 6) months from the start of treatment.
Neurological improvement was observed in two of nine patients (22.2%). The remaining four of nine patients (44.5%) achieved neurological stabilization that lasted for a median of 5 (95% confidence interval 2 - 19) months. The best radiological response was stable disease in five of nine patients (55.6%). No complete or partial responses were achieved according to criteria of the Response Assessment in Neuro-Oncology.
This preliminary outcome of an extended-access program was reported at the 2021 Society for Neuro-Oncology's 26th Annual Scientific Meeting and Education Day, from November 18 – 21.
https://www.practiceupdate.com/C/127819/56?elsca1=...
{Free access to this reporting.}
0 -
Breast Cancer Outcomes Following Immediate Breast Reconstruction With Implants Versus Autologous Flaps
- In this retrospective study, there were no significant differences in recurrence rates, distant metastases rates, or survival rates in patients with primary breast cancer who underwent immediate breast reconstruction after nipple-/ skin-sparing mastectomy with either implant-based reconstruction (IBR) or autologous flap reconstruction (AFR).
- Oncologic outcomes were similar in this population following IBR or AFR.
{No charge to access abstract. Charge or subscription to access full article. On my computer, the journal page blocked half the screen if I did not accept ALL cookies. Very annoying. The Practice Update page which offers reporting did NOT do this.}
0 -
A massive 8-year effort finds that much cancer research can't be replicated
"like research in the social sciences, cancer research has a replication problem.
Researchers with the Reproducibility Project: Cancer Biology aimed to replicate 193 experiments from 53 top cancer papers published from 2010 to 2012. But only a quarter of those experiments were able to be reproduced, the team reports in two papers published December 7 in eLife."
https://www.sciencenews.org/article/cancer-biology...
0 -
That's pretty scary!!!
0 -
Duration of Endocrine Therapy in Breast Cancer: How Much of a Good Thing Is Too Much?
Tailored Approach Based on Anatomic and Biologic Risks
We think these recent data are important for clinicians and women with breast cancer and offer a tailored approach based on anatomic and biologic risks. For postmenopausal women with stage I breast cancer, who have lower-risk histologic features or genomic risk scores, 5 years of adjuvant endocrine treatment is likely sufficient, particularly if that includes an aromatase inhibitor at some point. For patients with stage II cancers or limited nodal involvement, they suggest that a treatment course of around 7 years is likely to offer an advantage over 5 years. And, finally, for women with higher-risk tumors by virtue of stage or adverse biology, longer durations of around 10 years remain the standard recommendation. As always, it is important to weigh the benefits of longer treatment against the well-known side effects of therapy, such as arthralgias, osteoporosis, hair thinning, and genitourinary health. Hopefully, patients and clinicians can use these data to make well-informed, data-driven, shared decisions about the best course of therapy.
Dr. Trapani and Dr. Burstein are employed at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.
0 -
Users of AI, we are not crazy, SE exist:
Aromatase inhibitors have been associated with new onset autoimmune diseases.
Our cases suggest a link between aromatase inhibitors and inflammatory myopathies.
Cessation of the aromatase inhibitor should be considered if a myopathy develops.
https://www.sciencedirect.com/science/article/pii/S1297319X21001810?dgcid=rss_sd_all
0 -
Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer
0 -
Anyone know how to get information on SABCS?
There was something related to the trial I'm in but, I have no idea how to find whatever they did.
It should have been Wednesday Night 12/8 at SABCS 5-6:30 PM CT.
"OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer
Han HS, Disis M, Wesolowski R, Fisher C, Gandhi S, Chan N, Gwin W, Gogineni K, Mick R, Sierra Rodriguez C, Hogue D, Liu H, Costa R, Czerniecki B. Moffitt Cancer Center and Research Institute, Tampa, FL; University of Washington, Seattle, WA; Ohio State University, Columbus, OH; Indiana University School of Medicine, Indianapolis, IN; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Rutgers Cancer Institute of New Jersey, New Brunswick, NY; Emory Winship Cancer Institute, Atlanta, GA; University of Pennsylvania School of Medicine, Philadelphia, PA."
0 -
morrigan, you have to be registered as a delegate. I am one. I will try to get that info for you - I can access talks and presentations but the posters section is not working well for me (& others are having the same problem...)
0 -
Morrigan - the MODs usually post all sorts of information & data after the conference is over.
0
